http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
PTC Therapeutics (PTCT) Appoints Alethia Young to its Board
-
Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors
-
PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference
-
Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study
-
PTC Therapeutics (PTCT) Announces FDA Label Extension of Evrysdi to Include Infants
-
FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old
-
PTC Therapeutics (PTCT) Receives Positive CHMP Opinion for Upstaza for the Treatment of AADC Deficiency
-
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency
-
PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results
-
PTC Therapeutics (PTCT) Issues Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program
-
PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program
-
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
PTC Therapeutics (PTCT) Initiates PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease
-
PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease
-
PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
-
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Financial Results
-
PTC Therapeutics's (PTCT) Evrysdi Granted FDA Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy
-
FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy
-
PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program
-
PTC Therapeutics (PTCT) Provides Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference
-
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference
-
PTC Therapeutics' (PTCT) Waylivra Receives Innovative Drug Category Pricing in Brazil
-
Waylivra™ Receives Innovative Drug Category Pricing to Treat Familial Chylomicronemia Syndrome in Brazil
-
PTC Therapeutics to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
-
Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform
-
Evrysdi® Distinguished by Two Prestigious Awards for Outstanding Innovation in Drug Discovery
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
-
PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results
-
PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
-
PTC Announces Expansion of Translarna™ Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil
-
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results
-
PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility
-
Tegsedi® Receives Innovative Drug Category Pricing in Brazil
-
Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy
-
PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program
-
PTC Therapeutics (PTCT) Announces STRIDE Data Show Translarna Delays Loss of Ambulation by More Than Five Years in Boys with nmDMD
-
STRIDE Data Show Translarna™ Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy
-
PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community
-
PTC Therapeutics (PTCT) Announces Brazilian Approval of Waylivra
-
PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome
-
Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results

